Interstitial fluid pressure in tumors: Therapeutic barrier and biomarker of angiogenesis

Future Oncology

Volumn 4, Issue 6, 2008, Pages 793-802

  Milosevic, Michael ^a   Lunt, Sarah Jane ^a   Fyles, Anthony ^a   Hill, Richard P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Biomarker; Cancer; Cervic cancer; Chemotherapy; Interstitial fluid pressure; Radiotherapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CYTOKINE; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; ETOPOSIDE; GROWTH FACTOR; IMATINIB; IRINOTECAN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; RGS PROTEIN; SORAFENIB; TISSUE PLASMINOGEN ACTIVATOR; TOPOTECAN; VASCULOTROPIN A; VASCULOTROPIN C; TUMOR MARKER;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CAPILLARY PRESSURE; CYTOTOXICITY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HUMAN; INDIVIDUALIZATION; LYMPH NODE METASTASIS; PATIENT CARE; PREDICTION; PRESSURE MEASUREMENT; PRESSURE TRANSDUCER; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; REVIEW; TISSUE PRESSURE; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME; UTERINE CERVIX CANCER; ANIMAL; EXTRACELLULAR FLUID; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PRESSURE; VASCULARIZATION;

ANIMALS; EXTRACELLULAR FLUID; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PRESSURE; TUMOR MARKERS, BIOLOGICAL;

EID: 61449558421     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.6.793     Document Type: Review

References (62)

1. Bristow RG, Hill RP: Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8, 180-192 (2008).
2. Cairns R, Papandreou I, Denko N: Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 4, 61-70 (2006).
3. Moeller BJ, Richardson RA, Dewhirst MW: Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26, 241-248 (2007).
4. Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24-40 (2006).
5. Milosevic M, Fyles A, Hedley D et al.: Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 61, 6400-6405 (2001).
6. Fyles A, Milosevic M, Pintilie M et al.: Long-term performance of interstitial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother. Oncol. 80, 132-137 (2006).
7. Heldin CH, Rubin K, Pietras K, Ostman A: High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806-813 (2004).
8. Taghian AG, Abi-Raad R, Assaad SI et al.: Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol. 23; 1951-1961 (2005).
9. Boucher Y, Kirkwood JM, Opacic D: Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 51, 6691-6694 (1991).
10. Curti BD, Urba WJ, Alvord WG et al.: Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 53, 2204-2207 (1993).
11. Gutmann R, Leunig M, Feyh J et al.: Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 52, 1993-1995 (1992).
12. Nathan SS, DiResca GR, Casas-Ganem JE et al.: Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin. Cancer Res. 11, 2389-2397 (2005).
13. Jain RK: Determinants of tumor blood flow: a review. Cancer Res. 48, 2641-2658 (1988).
14. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK: Pathology: cancer cells compress intratumour vessels. Nature 427, 695 (2004).
15. Denko NC, Giaccia AJ: Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res. 61, 795-798 (2001).
16. Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res. 47, 3039-3051 (1987).
17. Wiig H, Rubin K, Reed RK: New and active role of the interstitium in control of interstitial fluid pressure: potential therapeutic consequences. Acta Anaesthesiol. Scand. 47, 111-121 (2003).
18. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK: Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 60, 4324-4327 (2000).
19. Baxter L, Jain R: Transport of fluid and macromolecules in tumors I. Role of interstitial pressure and convection. Microvasc. Res. 37, 77-104 (1989).
20. Boucher Y, Baxter LT, Jain RK: Interstitial pressure gradients in tissue isolated and subcutaneous tissues: implications for therapy. Cancer Res. 50, 4478-4484 (1990).
21. Boucher Y, Jain RK: Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 52, 5110-5114 (1992).
22. Guyton AC: Textbook of Medical Physiology. Sixth edition. WB Saunders Company, PA, USA (1981).
23. Lunt SJ, Kalliomaki TM, Brown A, Yang VX, Milosevic M, Hill RP: Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer 8, 2 (2008).
24. Milosevic MF, Fyles AW, Wong R et al.: Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 82, 2418-2426 (1998).
25. DiResta GR, Lee J, Larson SM, Arbit E: Characterization of neuroblastoma xenograft in rat flank. I. Growth, interstitial fluid pressure, and interstitial fluid velocity distribution prfiles. Microvasc. Res. 46, 158-177 (1993).
26. Rofstad EK Tunheim SH, Mathiesen B et al.: Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res. 62, 661-664 (2002).
27. Griffon-Etienne G, Boucher Y, Jain RK, Suit HD: Effects of needle insertion in tumors on interstitial fluid pressure. Microvasc. Res. 54, 174-177 (1997).
28. Skliarenko J, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP: Effects of the vascular targeting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res. 66, 2074-2080 (2006).
29. Milosevic MF, Fyles AW, Hill RP: The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int. J. Radiat. Oncol. Biol. Phys. 43, 1111-1123 (1999).
30. Ozerdem U, Hargens AR: A simple method for measuring interstitial fluid pressure in cancer tissues. Microvasc. Res. 70, 116-120 (2005).
31. Schnell CR, Stauffer F, Allegrini PR et al.: Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature implications for clinical imaging. Cancer Res. 68, 6598-6607 (2008).
32. Haider M, Sitartchouk I, Roberts TPL, Fyles A, Hashmi AT, Milosevic M: Correlations between dynamic contrast enhanced magnetic resonance imaging derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervix cancer. J. Magn. Reson. Imaging 25, 153-159 (2007).
33. McVeigh PZ, Syed AM, Milosevic M, Fyles A, Haider MA: Diffusion-weighted MRI in cervical cancer. Eur. Radiol. 18, 1058-1064 (2008).
34. Hassid Y, Furman-Haran E, Margalit R, Eilam R, Degani H: Noninvasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors. Cancer Res. 66, 4159-4166 (2006).
35. Milosevic M, Lunt SJ, Leung E et al.: Interstitial permeability and elasticity in human cervix cancer. Microvasc. Res. 75, 381-390 (2008).
36. Hori K, Saito S: Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br. J. Cancer 89, 1334-1344 (2003).
37. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004).
38. Lee C, Heijn M, di Tomaso E et al.: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic and hypoxic conditions. Cancer Res. 60, 5565-5570 (2000).
39. Wilhelm SM, Carter C, Tang L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
40. Pietras K, Ostman A, Sjoquist M et al.: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61, 2929-2934 (2001).
41. Willett CG, Boucher Y, di Tomaso E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004).
42. Winkler F, Frozin SV, Tong RT et al.: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 533-563 (2004).
43. Pietras K, Stumm M, Hubert M et al.: ST1571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 9, 3779-3787 (2003).
44. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
45. Vlahovic G, Rabbani ZN, Hendon JE 2nd, Dewhirst MW, Vujaskovic Z: Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br. J. Cancer 95, 1013-1019 (2006).
46. Wildiers H, Guetens G, De Boeck G et al.: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88, 1979-1996 (2003).
47. Dickson PV, Hamner JB, Sims TL et al.: Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res. 13, 3942-3950 (2007).
48. Fyles A, Milosevic M, Hedley D et al.: Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol. 20, 680-687 (2002).
49. Fyles A, Keane TJ, Barton M, Simm J: The effect of treatment duration in the local control of cervix cancer. Radiother. Oncol. 25, 273-279 (1992).
50. Diresta GR, Nathan SS, Manoso MW et al.: Cell proliferation of cultured human cancer cells are affected by the elevated tumor pressures that exist in vivo. Ann. Biomed. Eng. 33, 1270-1280 (2005).
51. Boucher Y, Lee I, Jain RK: Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc. Res. 50, 175-182 (1995).
52. Mollica F, Jain RK, Netti PA: A model for temporal heterogeneities of tumor blood flow. Microvasc. Res. 65, 56-60 (2003).
53. Baish JW, Netti PA, Jain RK: Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc. Res. 53, 128-141 (1997).
54. Gorski DH, Beckett MA, Jaskowiak NT et al.: Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
55. Nathan SS, Huvos AG, Casas-Ganem JE et al.: Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J. Orthop. Res. 26(11), 1520-1525 (2008).
56. Manome Y, Saeki N, Yoshinaga H, Watanabe M, Mizuno S: A culture device demonstrates that hydrostatic pressure increases mRNA of RGS5 in neuroblastoma and CHC1-L in lymphocytic cells. Cells Tissues Organs 174, 155-161 (2003).
57. Hamzah J, Jugold M, Kiessling F et al.: Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410-414 (2008).
58. Jain RK, Tong RT, Munn LL: Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67, 2729-2735 (2007).
59. Timke C, Zieher H, Roth A et al.: Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin. Cancer Res. 14, 2210-2219 (2008).
60. Pietras K, Rubin K, Sjoblom T et al.: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62, 5476-5484 (2002).
61. Vlahovic G, Ponce AM, Rabbani Z et al.: Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br. J. Cancer 97, 735-740 (2007).
62. Chiu JJ, Usami S, Chien S: Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis. Ann. Med. 1-10 (2008).